Bottom Fish Stocks (between .10 and$10)

[zenvesting]

BIPH sale over...patent new out....makes my previous post regarding Medtronic even more compelling:

Biophan Announces Allowance of Three U.S. Patents
Tuesday February 24, 11:24 am ET
Patents Cover Technology to Transmit Biosensor Information Within the Body to Devices Outside the Body


ROCHESTER, N.Y.--(BUSINESS WIRE)--Feb. 24, 2004--Biophan Technologies, Inc. (OTC BB: BIPH - News), an innovator, developer, and marketer of advanced biomedical technology, today announced today that three additional of its pending patents have been allowed by the United States Patent and Trademark Office. Allowance means that the patents will now be scheduled for issuance.
Noting that the patents cover the use of fiber-optics and photonic components to transmit biosensor information from within the body to a device or devices inside or outside the body, the patents also involve the use of fiber-optic components for MRI Safety and Image Compatibility. Fiber optic components are virtually impervious from interference from Magnetic Resonance Imaging, and also provide very high bandwidth data capacity useful for imaging and remote sensing. The teachings cover various photonic applications where light beams are converted to electricity for powering sensors and for providing therapeutics, or used to carry data back from the sensor or imaging device, and for adapting non-photonic devices to use fiber optics and low powered lasers.

Biophan previously announced the successful testing of a pacemaker using a fiber-optic lead to pace an animal's heart. These patents teach how many devices can use fiber-optics and photonics components to carry information and/or deliver power to a variety of devices, both implantable and those used in minimally invasive interventional medicine, and without potential tissue damage or imaging interference when used during an MRI procedure.

Electromagnetic Interference Immune Tissue Invasive System
http://www.biophan.com/patents/2.html
http://www.biophan.com/patents/2.pdf

MRI-Compatible Medical Device with Passive Generation of Optical Sensing Signals

http://www.biophan.com/patents/4.html

http://www.biophan.com/patents/4.pdf

Electromagnetic Interference Immune Tissue Invasive System
http://www.biophan.com/patents/3.html
http://www.biophan.com/patents/3.pdf

About Biophan Technologies, Inc.

Biophan Technologies develops and markets cutting-edge technologies used to make biomedical devices--such as cardiac pacemakers, surgical and diagnostic tools--safe and compatible with magnetic resonance imaging (MRI) equipment. The technology is also being used to create enhanced MRI contrast agents. Committed to growth through innovation and developmental leadership, Biophan and its licensors have four issued U.S. patents and over fifty patents pending, in areas including nanomagnetic particle coatings, radio frequency filters, polymer composites, and photonics. Biophan's technology will help realize its goal of one day making all biomedical devices capable of safely and successfully working with MRI. For more information, please visit www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of Biophan's MRI technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the acceptance by the market of Biophan's products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.



--------------------------------------------------------------------------------
Contact:
Biophan Technologies, Inc.
Investor Relations:
Carolyn Hotchkiss, 585/214-2407
or
Press Interviews:
Michael Weiner, 585/214-2441